Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Moodys
Merck
Queensland Health
Healthtrust
QuintilesIMS
Dow
Federal Trade Commission
Cerilliant

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,364,564

« Back to Dashboard

Summary for Patent: 9,364,564
Title:Pre-mixed, ready-to-use pharmaceutical compositions
Abstract: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
Inventor(s): Duncan; Michelle Renee (Glenview, IL), Gupta; Supriya (Sunnyvale, CA), Haas; David Hartley (Fremont, CA), Stephens; Norma V. (Skokie, IL), Zamiri; Camellia (Fremont, CA)
Assignee: EKR Therapeutics, Inc. (Cary, NC)
Application Number:12/645,169
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 9,364,564

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chiesi Usa Inc CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-004 Nov 7, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Chiesi Usa Inc CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Chiesi Usa Inc CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-002 Jul 31, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Chiesi Usa Inc CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-005 Nov 7, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,364,564

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,370,586 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
7,612,102 Pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
7,659,290 Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
9,549,994 Compositions of nicardipine and sulfoalkylated .beta.-cyclodextrin ➤ Subscribe
8,455,524 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
7,659,291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,364,564

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 572225 ➤ Subscribe
Canada 2650922 ➤ Subscribe
Canada 2895102 ➤ Subscribe
China 101484006 ➤ Subscribe
China 101484136 ➤ Subscribe
European Patent Office 2012788 ➤ Subscribe
European Patent Office 2018152 ➤ Subscribe
Israel 194799 ➤ Subscribe
Israel 194800 ➤ Subscribe
Japan 2009534388 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Cantor Fitzgerald
Cerilliant
McKesson
Julphar
Accenture
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot